Calvin Cohen, M.D., M.Sc. is an Executive Director within the Global HIV Medical Affairs department of Gilead Sciences. He joined Gilead in February 2015 after 25 years of maintaining an HIV-focussed Internal Medicine practice. His primary role within Global Medical Affairs is serving as the Global Medical Lead for tenofovir alafenamide, and the portfolio of regimens based on TAF.
Dr. Cohen received his MD degree from the Albert Einstein College of Medicine in New York. He received his Master of Science degree from the Harvard School of Public Health and completed his residency and fellowship at Beth Israel Hospital in Boston, USA.
Prior to joining Gilead, Dr. Cohen's research focus was on HIV antiretroviral trials since 1985. He served as the Director of Research for the non-profit Community Research Initiative of New England which was a site for the NIH funded Insight network. He maintained an Internal Medicine practice focussed on HIV for 25 years within the Harvard system was a part-time Clinical Instructor at Harvard Medical School.
